FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …

Abstract The Cancer and Leukemia Group B (CALGB), now part of the Alliance for Clinical
Trials in Oncology, conducted a multicenter, single-arm, phase 2 study in patients≥ 60 …

In older/unfit newly diagnosed patients with FLT3 mutated acute myeloid leukemia (AML),
lower intensity chemotherapy (LIC) in combination with either a FLT3 inhibitor or with …

AML is a heterogeneous malignant clonal disorder with an overall incidence of 4.1 per
100,000 individuals. 1 The prognosis, although variable, is generally poor. Although the …

Abstract Purpose of Review This review aims to summarize the pathophysiology, clinical
presentation, and management of acute myeloid leukemia (AML) with FMS-like tyrosine …

Background: FLT3 mutations are associated with a poor prognosis in both newly diagnosed
(ND) and relapsed/refractory (R/R) acute myeloid leukemia (AML). Gilteritinib is a potent oral …

FMS-like tyrosine kinase 3 (FLT3) mutations, the most frequently detected genetic
aberrations in patients with acute myeloid leukemia (AML), are identified in approximately …

Background: Gilteritinib improves response rates and overall survival (OS) compared with
chemotherapy in patients (pts) with relapsed/refractory (R/R) FLT3-mutated acute myeloid …

BACKGROUND FLT3–internal tandem duplication (ITD) mutations are found in
approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have …

In the international randomized phase 3 RATIFY (Randomized AML Trial In FLT3 in patients
less than 60 Years old) trial, the multikinase inhibitor midostaurin significantly improved …